X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1946) 1946
Publication (135) 135
Conference Proceeding (121) 121
Book Review (85) 85
Patent (50) 50
Book Chapter (13) 13
Book / eBook (10) 10
Government Document (1) 1
Magazine Article (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (698) 698
humans (451) 451
male (390) 390
female (324) 324
animals (277) 277
middle aged (189) 189
analysis (176) 176
adult (160) 160
aged (154) 154
neurosciences (152) 152
rats (137) 137
immunology (100) 100
risk factors (99) 99
transplantation (99) 99
infectious diseases (97) 97
pharmacology & pharmacy (97) 97
cannabinoids (94) 94
health aspects (90) 90
mice (85) 85
surgery (85) 85
environmental sciences (78) 78
research (74) 74
microbiology (67) 67
engineering, civil (63) 63
spain (61) 61
retrospective studies (54) 54
basal ganglia (53) 53
endocannabinoids (53) 53
rats, wistar (51) 51
internal medicine (50) 50
brain (49) 49
disease (49) 49
construction & building technology (48) 48
care and treatment (47) 47
treatment outcome (47) 47
receptors (46) 46
cardiac & cardiovascular systems (45) 45
medicine, general & internal (45) 45
prospective studies (43) 43
time factors (43) 43
dopamine - metabolism (42) 42
infection (42) 42
aged, 80 and over (41) 41
activation (40) 40
adolescent (39) 39
biochemistry & molecular biology (39) 39
management (39) 39
cannabinoid receptors (38) 38
disease models, animal (38) 38
marine & freshwater biology (38) 38
mortality (38) 38
neuroprotection (38) 38
sediments (38) 38
tetrahydrocannabinol (38) 38
usage (38) 38
young adult (38) 38
clinical neurology (37) 37
dopamine (37) 37
neurons (37) 37
multidisciplinary sciences (36) 36
anandamide (35) 35
cannabinoid (35) 35
medicine (35) 35
prognosis (35) 35
spain - epidemiology (35) 35
chemistry (34) 34
materials science, multidisciplinary (34) 34
mexico (34) 34
parkinson's disease (34) 34
studies (34) 34
expression (33) 33
infections (33) 33
neurology (33) 33
receptors, cannabinoid (33) 33
cancer (32) 32
cell biology (32) 32
follow-up studies (32) 32
kidney transplantation (32) 32
organ transplant recipients (32) 32
cannabinoids - pharmacology (31) 31
epidemiology (31) 31
geosciences, multidisciplinary (31) 31
model (31) 31
reinforced concrete (31) 31
article (30) 30
oncology (30) 30
survival (30) 30
therapy (30) 30
gastroenterology & hepatology (29) 29
medical research (29) 29
physiological aspects (29) 29
rats, inbred strains (29) 29
food science & technology (28) 28
human necessities (28) 28
kidneys (28) 28
patients (28) 28
abridged index medicus (27) 27
child (27) 27
endocannabinoid system (27) 27
life sciences (27) 27
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1678) 1678
Spanish (394) 394
Portuguese (50) 50
French (21) 21
German (9) 9
Chinese (2) 2
Croatian (1) 1
Danish (1) 1
Hungarian (1) 1
Italian (1) 1
Korean (1) 1
Lithuanian (1) 1
Polish (1) 1
Russian (1) 1
Serbian (1) 1
Slovenian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 11/2013, Volume 369, Issue 22, pp. 2093 - 2104
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 02/2015, Volume 60, Issue 3, pp. 405 - 414
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2013, Volume 369, Issue 14, pp. 1327 - 1335
Alogliptin, a new antihyperglycemic agent of the DPP-4 class, was shown to have no significant effect on cardiovascular risk over a median treatment period of... 
INHIBITOR ALOGLIPTIN | MEDICINE, GENERAL & INTERNAL | MYOCARDIAL-INFARCTION | CLINICAL-TRIALS | VASCULAR OUTCOMES | RISK | COMPLICATIONS | THERAPIES | CARDIOVASCULAR SAFETY | MELLITUS | BLOOD-GLUCOSE CONTROL | Hypoglycemic Agents - therapeutic use | Double-Blind Method | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Uracil - therapeutic use | Male | Myocardial Infarction - complications | Myocardial Infarction - drug therapy | Uracil - adverse effects | Angina, Unstable - drug therapy | Piperidines - therapeutic use | Angina, Unstable - complications | Piperidines - adverse effects | Cardiovascular Diseases - mortality | Female | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Diabetes Mellitus, Type 2 - complications | Uracil - analogs & derivatives | Type 2 diabetes | Care and treatment | Acute coronary syndrome | Patient outcomes | Risk factors | Myocardial infarction | Heart attacks | Cardiovascular disease | Angina | Drug development | Hemoglobin | Diabetes mellitus (non-insulin dependent) | Drug dosages | Cerebral infarction | Stroke | Peptidase | Statistical analysis | Diabetes mellitus | Pancreatitis | Committees | FDA approval | Hypoglycemia | Angina pectoris | Studies | Product development | Diabetes | Acute coronary syndromes | Cardiovascular diseases | Health risk assessment | Cancer | Index Medicus | Abridged Index Medicus
Journal Article